Global Ophthalmology Therapeutics Frontier Pharma Market 2016: Growing Opportunities for Biologic Products - Research and Markets

DUBLIN, Dec 5, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way" drug pipelines to their offering.

There are a total of 158 first-in-class pipeline products in development for ophthalmology indications, representing 36% of the 438 pipeline products for which there is a disclosed molecular target. They appear generally promising in terms of safety and efficacy, and appear to have significant potential to strengthen the treatment landscape for key ophthalmological conditions - as well as representing promising commercial opportunities.

The visual system, including the eye and its surrounding structures, can be affected by a number of pathological conditions. Ophthalmology encompasses a diverse range of indications affecting this system. Key diseases within this therapy area include glaucoma, age-related macular degeneration, diabetic macular edema, diabetic retinopathy and dry eye syndrome.

While treatments for dry eye syndrome are generally able to control its symptoms in the majority of patients, the other four diseases are progressive, chronic, incurable and can lead to visual impairment and even blindness if not adequately treated. Treatment is aimed at managing the disease, in order to reduce the severity of symptoms and to slow progression, rather than being curative.

Scientific advancements over recent decades have revealed a broad range of novel potential molecular targets, enabling progress in a previously stagnant field. This is reflected by the high number of products in development, with 782 pipeline products currently in the ophthalmology therapy area pipeline.

Many first-in-class products in the current ophthalmology pipeline have previously been involved in licensing and co-development deals. This indicates a strong degree of strategic consolidation uptake for first-in-class products in ophthalmology, and a willingness on the part of companies to invest in innovative products that show promise in both preclinical and clinical trials.

Key Topics Covered:

1. Tables & Figures

2 Executive Summary
2.1 Market Landscape Poised for Entry of Novel Products
2.2 Moderately-Sized but Strong First-in-Class Pipeline
2.3 Strong Uptake of First-in-Class Products in Strategic Consolidations

3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Development Remains Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation

4 Clinical and Commercial Landscape
4.1 Therapy Area Overview
4.2 Disease Symptoms
4.3 Epidemiology and Etiology
4.4 Diagnosis
4.5 Pathophysiology
4.6 Treatment Options
4.7 Prognosis
4.8 Overview of Marketed Products in Ophthalmology
4.8.1 Molecule Type and Target Analysis

5 Assessment of Pipeline Product Innovation
5.1 Ophthalmology Pipeline by Molecular Target
5.2 Comparative Distribution of Programs between the Ophthalmology Market and Pipeline by Therapeutic Target Family
5.3 First-in-Class Pipeline Programs Targeting Novel Molecular Targets

6 Signaling Network, Disease Causation and Innovation Alignment
6.1 Complexity of Signaling Networks in Ophthalmology
6.2 First-in-Class Matrix Assessment

7 First-in-Class Target Evaluation
7.1 Pipeline Programs Targeting RPE65 and RBP4
7.2 Pipeline Programs Targeting Eotaxin-1 and CCR3
7.3 Pipeline Programs Targeting LRP6
7.4 Pipeline Programs Targeting TGF-Beta 2
7.5 Pipeline Programs Targeting NGF, and LNGFR and TrkA Nerve Growth Factor Receptors
7.6 Pipeline Programs Targeting Serine Protease HtrA1
7.7 Conclusion

8 Deals and Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Licensing Deals
8.3 Co-development Deals
8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals

9 Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/g327gk/frontier_pharma

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets